Living channels.
Programmable flow.

A self-assembling microfluidic platform built from engineered Neurospora crassa, with septal pore valves addressed by light instead of pneumatics. No cleanroom in the critical path.

10,440 KO pairs screened Optically addressed valving US provisional filed Two validation gates ahead
The septal pore valve in its dark and lit states In the dark, the septal pore is open and cytoplasm flows between hyphal compartments. Under 450 nm blue light, HEX1 is recruited to anchors at the pore rim and assembles into a plug that occludes the pore, stopping flow. The pore is approximately 150 nanometres across. DARK — FLOW OPEN ~150 nm pore 450 nm — FLOW CLOSED 450 nm in pore occluded Removing light reverses it: thermal reversion reopens the pore with no input signal.
The organism already builds a dense array of these pores. Our constructs are designed to make them addressable — designed and modeled, not yet measured.

Microfluidics is stuck in the cleanroom.

Every experiment starts with a photomask and weeks of fabrication. Biology moved on — microfluidics hasn't.

01

2–4 weeks per chip, $5k–$20k per mask

PDMS fabrication requires a cleanroom. Each design change means a new photomask — slow iteration, high cost, high barrier to entry.

02

Passive channels — no programmability

Active valves require complex external pneumatic systems. No built-in actuation. No design reusability across projects.

03

Single-use waste — clogging kills the chip

Channel fouling is terminal. Each clog means discarding the device and restarting fabrication from scratch.

$25B

Microfluidics market by 2028 — growth limited by fabrication bottlenecks and passive chip designs.

Every experiment starts with a cleanroom. Biology moved on — microfluidics hasn't.

One fungus. One week. Zero cleanroom.

Sivoro replaces photolithography with engineered fungi that self-assemble into precision microfluidic channels.

Feature Sivoro Living Chip Conventional PDMS
Fabrication Fungus grows channels Photolithography (cleanroom)
Valves Light-addressed, 450 nm, intrinsic Pneumatic, external control lines
Valve density Set by projection optics Set by control-line routing
Iteration Days (transform strain) Weeks (redesign mask)
Channel recovery Hyphal turnover (target behavior) Terminal (chip disposal)

Five patent families, three technical layers

From metabolic chassis to optogenetic valve to physical scaffold, all covered by US provisional application 64/087,071.

Layer 1 — Chassis

Metabolically Orthogonal N. crassa

Engineered to run on xylose while uptake of reagent sugars and metabolites is substantially reduced — roughly 87% of reagent uptake blocked. Six-gene knockout selected in silico from 10,440 combinations screened.

Composition of matter Screening method

Layer 2 — Valve

Optogenetic Septal Pore Valve

Blue light (450 nm) drives recruitment at the septal pore. LOV2-Jα-HEX1 fusion protein + SPA1-ePDZ pore-rim anchor. Designed and modeled; dark/lit contrast is what Gate 2 measures.

Optogenetic construct Flow control method

Layer 3 — Scaffold

H-Tree Scaffold & Integration

Parametric design (10×10 mm, 16 ports). Compatible with SU-8/PDMS or direct printing. Channel dimensions engineered for 2–8 hyphae (13–20 µm width, 15 µm depth).

Fungal-specific geometry Co-culture methods

Computational phases complete.
Two experimental gates next.

Metabolic modeling, the knockout screen, valve design, and scaffold design are done. Two biophysical measurements now determine whether the valve works: HEX1 oligomerization by SEC-MALS, and light-dependent binding by BLI.

Chassis construction follows those results rather than preceding them.

View the validation sequence →
  1. Metabolic modeling, KO screen, valve design, scaffold design

    Complete — all computational

  2. SEC-MALS on CompA_v3

    Gate — does HEX1 oligomerize in the fusion? Mw ≥ 1000 kDa

  3. BLI — Jα motif to ePDZ anchor

    Gate — does it bind under light? ≥10× dark/lit contrast

  4. Six-gene chassis construction

  5. Valve function in hypha

  6. Prototype chip colonization

  7. First academic beta site

The only living, self-assembling microfluidic platform

Sivoro occupies a unique position: simple fabrication, active biological control. No competitor is in this quadrant.

Competitor Sivoro Advantage
Emulate, Inc.No living channels; $200k+ instruments
CN Bio InnovationsLower cost, faster iteration
MicronitNo cleanroom required
Fluidigm / Standard BioTools10× lower price; biological actuation

X axis: Active control · Y axis: Fabrication simplicity

Computational validation complete

10,440

Knockout pairs screened in silico

16

Strains clearing the chip-integration threshold

2

Optogenetic constructs designed, codon-optimized, and structurally modeled

7,600+

Lines of modeling and analysis code

145

Gene candidate pool behind the screen

64/087,071

US provisional application, filed June 10, 2026

IP Status

US provisional application 64/087,071, filed June 10, 2026 · 5 claim families · sole applicant, no institutional encumbrance

$1.5M

18 months runway to a functional prototype

Round
Seed
Pre-money
$6M
Post-money
$7.5M
Runway
18 mo

The round starts with two measurements, SEC-MALS and BLI, that decide whether the valve works, then carries the work through chassis construction to a prototype chip. Series A follows in Q4 2027.

View Investor Materials → Download Pitch Deck